Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
Month
1
2
3
4
5
6
7
8
9
10
11
12
18
2024-01
Boan Biotech Obtains ANVISA GMP Certification
15
2024-01
All Subjects Enrolled for Intl Phase 3 Study of Boan’s Denosumab
28
2023-12
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
30
2023-10
1st Patient Enrolled in Phase 3 Study of Boan’s Nivolumab
27
2023-09
The Results of a Phase I Clinical Trial Comparing Boan Biotech’s BA1102 with XGEVA® Published in Journal of Bone Oncology
29
2023-08
Boan Biotech's BA1202 Administered to First Subject
28
2023-08
Boan Biotech Announces 2023 Half Year Results
16
2023-05
Boan Biotech’s BA1202 Approved for Clinical Trial The First Novel CEA/CD3 Bispecific Antibody in China
16
2023-05
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China
16
2023-05
Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302
1
2
3
4
5